Market Overview

Regeneron Pharmaceuticals Spokesperson Declines Comment on Earlier Takeover Chatter

Related REGN
Lightning Round: Jim Cramer Shares His Thoughts On T-Mobile, Electronic Arts, And More
31 Stocks Moving In Thursday's Mid-Day Session
Buy Regeneron - Cramer's Lightning Round (12/14/17) (Seeking Alpha)
Related SNY
3 Stocks In Focus As Biotech M&A Hopes For 2018 Rise
Benzinga's Top Upgrades, Downgrades For December 1, 2017
Biotech Forum Daily Digest: Impacts Of Tax Reform (Seeking Alpha)

Regeneron (NASDAQ: REGN) spokesperson Peter Dworkin, while declining comment on earlier takeover chatter involving Sanofi (NYSE: SNY), did say that the two companies have a solid working relationship and have stated it would be advantageous to keep the relationship going as it is now, as separate companies.

Sanofi is Regeneron's largest shareholder currently. There is a standstill agreement in place preventing Sanofi from acquiring more than 30% of Regeneron's shares.

Regeneron shares spiked to a high of $145.81 on Thursday.

Posted-In: News Rumors M&A Movers


Related Articles (REGN + SNY)

View Comments and Join the Discussion!